Profile data is unavailable for this security.
About the company
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
- Revenue in USD (TTM)28.34m
- Net income in USD-250.66m
- Incorporated2017
- Employees305.00
- LocationBicycle Therapeutics PLCBlocks A & B, Portway Building, Granta PCAMBRIDGE CB21 6GSUnited KingdomGBR
- Phone+44 122 326 1503
- Websitehttps://www.bicycletherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 379.48m | 4.00 | -- | 172.92 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 380.48m | 56.00 | -- | 1.20 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 383.95m | 16.00 | -- | 4.56 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Organogenesis Holdings Inc | 564.17m | 15.85m | 385.92m | 854.00 | 32.25 | 1.27 | 11.20 | 0.6841 | 0.093 | 0.093 | 4.30 | 3.42 | 1.03 | 4.93 | 3.45 | 660,619.40 | 6.75 | 6.67 | 8.06 | 8.08 | 75.62 | 75.86 | 6.56 | 6.39 | 3.32 | -- | 0.0487 | 0.00 | 17.04 | 10.77 | 2,236.82 | 3.04 | -4.35 | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 389.91m | 106.00 | -- | 2.47 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 397.48m | 305.00 | -- | 0.6421 | -- | 14.03 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 397.75m | 32.00 | -- | 1.54 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 398.23m | 104.00 | 20.54 | 5.62 | 18.78 | 3.19 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 405.16m | 27.00 | -- | 7.85 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 405.53m | 140.00 | -- | 1.11 | -- | 3.58 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Ginkgo Bioworks Holdings Inc | 170.16m | -312.76m | 415.42m | 485.00 | -- | 0.8069 | -- | 2.44 | -5.64 | -5.64 | 3.07 | 8.74 | 0.1363 | -- | 7.29 | 350,835.10 | -25.05 | -66.61 | -27.27 | -72.83 | 72.39 | 66.71 | -183.81 | -395.48 | -- | -- | 0.00 | -- | -25.06 | 17.29 | 42.83 | -- | -33.24 | -- |
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 415.77m | 60.00 | -- | -- | -- | 82.26 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| Upstream Bio Inc | 2.80m | -122.77m | 416.10m | 52.00 | -- | 1.10 | -- | 148.66 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 419.80m | 34.00 | -- | 3.32 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Bicycle Therapeutics PLC's reporting currency: US Dollar USD
50.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 02 Jan 2026 | 10.96m | 21.94% |
| Armistice Capital LLCas of 31 Dec 2025 | 3.24m | 6.48% |
| Westfield Capital Management Co. LPas of 31 Dec 2025 | 3.02m | 6.04% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 1.67m | 3.35% |
| Long Focus Capital Management LLCas of 31 Dec 2025 | 1.63m | 3.27% |
| Candriam Belgium SAas of 31 Dec 2025 | 1.19m | 2.39% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 1.17m | 2.35% |
| Principal Global Investors LLCas of 31 Dec 2025 | 1.15m | 2.30% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 584.77k | 1.17% |
| BNP Paribas Asset Management USA, Inc.as of 31 Dec 2025 | 568.23k | 1.14% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
